Categories: FitnessHealthcareNews

MedBright AI Appointments Brandon Kou as Director

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) — MedBright AI Investments Inc. (the “Company” or “MedBright AI”) (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Brandon Kou has joined MedBright AI as a Director, effective February 3, 2025, replacing Jaime Gerber.

Brandon Kou is a Managing Director at Wildcat Equity Partners, a family office based in the US investing in healthcare, media, technology, and infrastructure.

Previously, he was CEO and board member of Leef Brands, a publicly traded MSO (multi-state operator) in the legalized cannabis space. Under his guidance, Leef acquired multiple brands and companies leading to an eventual merger with one of the largest manufactures in the state of California. Mr. Kou was responsible for all aspects of the business including M&A, all public market activities and general strategy for the company taking it from a small single brand focused company to one of the largest operators in the US.

Mr. Kou co-founded Block Partners, a merchant banking and advisory group for blockchain and distributed ledger technology companies. He also co-founded Mavan Capital Partners, an investment firm focused on bringing technology opportunities to the Canadian capital markets.

Earlier, Mr. Kou was Co-Founder and General Manager of Steve Nash Enterprises, managing a portfolio of companies in media/entertainment, sports, and health/wellness, including Indochino, Sharecare, the Vancouver Whitecaps, Onebode and the Steve Nash Sports Club and Fitness World. He also ran Meathawk, a film production company. In addition to his responsibilities at Steve Nash Enterprises, Mr. Kou served as a Board of Directors proxy for Steve Nash Sports Club and Fitness World, a growing chain fitness clubs in Vancouver co-founded by Mark Mastrov. 

Mr. Kou’s background includes investment banking at Houlihan Lokey, and he brings strong knowledge and experience within the capital markets. He holds a degree from USC’s Marshall School of Business.

The Company announces that 1,250,000 options have been granted to certain directors and officers at $0.035 for five years.

The Company expresses appreciation to Dr. Jamie Gerber for his contribution and wishes him the best in his future endeavours.

About MedBright AI Investments Inc.

Medbright AI is a capital allocator focused on investing in diversified industries, including technology, health care and artificial intelligence. These include both public and private companies. Medbright has a focus on near-term and midterm high-quality opportunities with strong return potentials while maintaining its commitment to governance.

For further information, please contact:

MedBright AI Investments Inc.
Mr. Christopher Cherry, Interim Chief Executive Officer
Email: investors@medbright.ai
Phone: (604) 602-0001
www.medbright.ai

Staff

Recent Posts

Mobile-health Network Solutions Announces Share Repurchase Program of up to 214,000 Shares

Singapore, Singapore--(Newsfile Corp. - June 5, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or…

2 hours ago

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a…

2 hours ago

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

Dr. Lessieur-Contreras will continue her groundbreaking research on understanding the early stages of diabetic retinopathy…

2 hours ago

Precision Optics Expands Facilities to Meet Growing Backlog

Company signs lease to move corporate offices and engineering development to Littleton, MA Move allows…

2 hours ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a…

2 hours ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009…

2 hours ago